The stock faces near-term delisting risk and severe operational contraction. Watch for a potential reverse stock split to regain Nasdaq compliance and any partnership announcements for the paused heme program. The pivot to early-stage solid tumor candidates is high-risk and likely years from value inflection. Traders should expect continued volatility and potential further downside.
Price Chart
Executive Summary
TScan Therapeutics announced a drastic strategic reorganization: a 75% workforce reduction, termination of its CFO and CMO, and a pause on its lead heme malignancy program (Phase 3 ALLOHA-2) due to capital constraints. The company will focus on early-stage in vivo solid tumor candidates (PRAME and MAGE-A4) and expects cumulative cost savings of $55M through 2027, extending cash runway into Q4 2027. Simultaneously, it received a Nasdaq minimum bid price deficiency notice, creating delisting risk. The combination of severe restructuring, executive departures, and delisting notice signals acute financial distress.
Key Facts
- Workforce reduction of approximately 75% (Strategic Reorganization).
- Expected restructuring charges of ~$4.1 million in employee-related costs.
- CFO Jason Amello and CMO Chrystal Louis terminated; CEO Gavin MacBeath assumes principal financial and accounting officer duties.
- Received Nasdaq deficiency notice for minimum bid price non-compliance; 180-day cure period until February 23, 2027.
- Paused further enrollment in Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital; 7 patients already enrolled on treatment arm.
- Strategic refocus on in vivo solid tumor program: two candidates (PRAME and MAGE-A4) advanced to IND-enabling studies.
- Cumulative cost savings of $55.0 million expected through end of 2027.
- Cash, cash equivalents and marketable securities as of June 30, 2026 expected to fund operations into Q4 2027.
Financial Impact
Restructuring charges of ~$4.1M; cumulative cost savings of $55M through 2027; cash runway extended into Q4 2027.
Risk Factors
- Failure to regain Nasdaq minimum bid price compliance leading to delisting.
- Inability to secure strategic partnerships for heme or autoimmune programs.
- Clinical or regulatory setbacks in the early-stage solid tumor program.
- Further cash burn or need for dilutive financing before reaching milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-379343 |
| Document: d309786dex992.htm | 0001193125-26-379343 |
| Document: d309786dex991.htm | 0001193125-26-379343 |
| Document: 0001193125-26-379343-index-headers.html | 0001193125-26-379343 |
| Document: 0001193125-26-379343-index.html | 0001193125-26-379343 |
| Document: 0001193125-26-379343.txt | 0001193125-26-379343 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $0.3204 $0.3119 | ▼ −2.65% | ▼ −2.43% | $0.3242 (+1.19%) |
Sep 2, 2026 4w ago | 8-K | $0.3810 $0.3179 | ▲ +16.56% | ▲ +15.60% | $0.3242 (+14.91%) |
Aug 18, 2026 6w ago | 8-K | $0.7500 $0.7774 | ▼ −3.65% | ▼ −4.04% | $0.3242 (+56.77%) |
Aug 12, 2026 7w ago | 8-K | $0.7730 $0.7500 | ▲ +2.98% | ▲ +2.53% | $0.3242 (+58.06%) |
Aug 12, 2026 7w ago | Press Release | $0.7730 $0.7500 | ▲ +2.98% | ▲ +2.53% | $0.3242 (+58.06%) |
Jun 22, 2026 14w ago | 8-K | $0.8651 $0.9775 | ▲ +12.99% | ▲ +13.45% | $0.3242 (−62.52%) |
Jun 22, 2026 14w ago | Press Release | $0.8651 $0.9688 | ▲ +11.99% | ▲ +14.06% | $0.3242 (−62.52%) |
May 6, 2026 21w ago | 8-K | $1.25 $1.15 | ▼ −8.00% | ▼ −9.13% | $0.3242 (−74.06%) |
Apr 2, 2026 26w ago | 8-K | $1.01 $1.05 | ▲ +3.96% | ▲ +0.34% | $0.3242 (−67.90%) |
Mar 4, 2026 30w ago | Press Release | $1.08 $1.15 | ▲ +6.48% | ▲ +7.81% | $0.3242 (−69.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access